DocMorris: Rx Acceleration and AI-First Strategy Unlock a Guidance Raise
Record Rx growth, expanding digital services, and tighter cost control lift the FY26 outlook.
DOCM.SW · Earnings Call · 2026-08-18
A Pivotal Quarter
DocMorris's H1 2026 results marked a decisive inflection. Revenue grew 13.4% in local currency, with Rx customer acquisition accelerating and co payment strategy driving market share gains. The company raised its full-year guidance, narrowing the EBITDA loss range and signaling confidence in hitting breakeven within the year.Rx Momentum and Co-payment Leverage
The core engine is the eRx business. The co-payment exemption has been a powerful lever, with management emphasizing its economic rationality. In the Q&A, Walter Hess explained: “the step from the bonus model before to the co-payment is relatively small” — Walter Hess, CEO · 2026-08-18, adding that the marketing optimization more than offsets the cost. This strategy has driven a 38% increase in Rx revenues in H1, accelerating to 46% in Q2, and continued momentum into Q3. Co-payment coverage has also fostered loyalty: latest eRx cohorts are 4.5x more loyal than paper Rx cohorts. The upcoming rise in statutory co-payments in 2027 is seen as a tailwind, as it increases price sensitivity and directs more patients online. This builds on earlier conviction: in 2025, the CFO had noted “the bonus and the co-payment that's a very strong instrument” — Daniel Wüest, CFO · 2026-03-24.AI-First: A New Cost and Growth Engine
The AI-First strategy, announced in June, is now fully integrated. The AI health assistant has been rolled out platform-wide, and management expects over CHF 15 million in recurring annual savings by end-2027, with 75% hitting EBITDA. Walter Hess highlighted the milestone: “We have successfully completed the full rollout of our AI health and shopping assistant across the entire DocMorris desktop, mobile website and app.” — Walter Hess, CEO · 2026-08-18 This, combined with a CHF 14 million reduction in marketing expenses, has improved the marketing efficiency ratio by 310 basis points. AI health initiatives are not just cost savings but also drive conversion, with assistant users showing higher engagement and order frequency. The earlier commitment to efficiency remains evident, as management had said in April: “we continuously improve the marketing mix” — Walter Hess, Chief Executive Officer · 2026-04-17.Digital Services and Retail Media Soar
TeleClinic revenue grew 48%, with EBITDA doubling, while Retail Media (dmr Advertising) surpassed EUR 10 million in net sales, growing over 100% year-on-year. These high-margin businesses are lifting the overall margin structure. Retail Media now operates as the #1 healthcare ad network in Germany, with a mid-double-digit EBITDA margin. The company's ability to monetize its platform through advertising and telemedicine is a key differentiator.Raising the Bar
DocMorris raised its FY26 external revenue growth guidance to 9-13% (from 3-12%) and narrowed adjusted EBITDA loss to CHF 10-17.5 million. The path to EBITDA breakeven is clearer, with operating cash flow improving by CHF 35 million year-on-year. Daniel Wüest, CFO, noted: “the current trading definitely would maybe justify a little stance of more guiding more aggressive.” — Daniel Wüest, CFO · 2026-08-18 As Walter Hess concluded,This confidence is grounded in past discipline and execution. The company has deliberately shifted marketing spend from high-cost TV to efficient digital channels, reducing the indirect cost ratio by 20 basis points. With a strong liquidity position of nearly CHF 100 million, DocMorris is well-positioned to achieve free cash flow breakeven in 2027.the lamps are on green.